Mingwei Liu

TL;DR: The proteomic stratification of early-stage hepatocellular carcinoma presented in this study provides insight into the tumour biology of this cancer, and suggests opportunities for personalized therapies that target it.

TL;DR: A mutation and proteome dataset for 84 DGC patients is presented, identifying three major classes of DGC and indicating potential targets for therapy and the benefit of proteomic analysis in cancer molecular subtyping.

TL;DR: A transcription factor (TF) DNA-binding activity-centered multi-dimensional proteomics landscape of the mouse liver is presented, which includes DNA- binding profiles of different TFs, phosphorylation, and ubiquitylation patterns, the nuclear sub-proteome, the whole proteome as well as the transcriptome, to portray the hierarchical circadian clock network of this tissue.

TL;DR: A fast sequencing (Fast-seq) workflow of the use of dual reverse phase high performance liquid chromatography - mass spectrometry (HPLC-MS) with a short gradient to achieve the same proteome coverage in 0.5 day is reported.

TL;DR: The development of an affinity reagent that permits identification of endogenous TFs at the proteome scale and applies catTFRE on the evaluation of drug effects, which described a panoramic view of TF activations and provided candidates for the elucidation of molecular mechanisms of drug actions.